Response | Week | Modified-release prednisone | Immediate-release prednisone | ||
---|---|---|---|---|---|
Per protocol population (N=26) | Full analysis population (N=32) | Per protocol population (N=22) | Full analysis population (N=30) | ||
Complete response* (n (%)) | 1 | 3 (11.5) | 5 (15.6) | 4 (18.2) | 4 (13.3) |
2 | 7 (26.9) | 9 (28.1) | 7 (31.8) | 7 (23.3) | |
4 | 14 (53.8) | 17 (53.1) | 9 (40.9) | 10 (33.3) | |
Partial response† (n (%)) | 1 | 8 (30.8) | 8 (25.0) | 1 (4.5) | 1 (3.3) |
2 | 11 (42.3) | 13 (40.6) | 2 (9.1) | 2 (6.7) | |
4 | 6 (23.1) | 8 (25.0) | 3 (13.6) | 4 (13.3) |
*Complete response was defined as all three of the following: (1) ≥70% improvement from baseline in the polymyalgia rheumatica visual analogue scale, (2) ≥70% reduction in the duration of morning stiffness and (3) ≥70% reduction in the C reactive protein (CRP) value (or CRP <2× upper limit of normal).
†Partial response was defined as two of the above three criteria being met.